Scientists created a programmable RNA repair tool that selectively replaces harmful RNA regions while preserving healthy ...

KRRO-110 miss drives overhaul; KRRO-121/111 show preclinical promise. Click here to read my most recent analysis of the stock ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...

Chinese researchers have reported the first clinical use of a domestically developed RNA-editing technology to treat Duchenne ...

Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular therapies. Review: RNA ...

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not without risk. When this type of "genetic surgery" is performed on DNA, for ...

Imagine your DNA as a set of instructions or a recipe book that tells your body how to make everything it needs to function, from proteins to cells. Every time the body needs to build something, it ...

RNA editing in plant mitochondria and chloroplasts is a post-transcriptional process that alters specific nucleotide residues, most commonly converting cytidine to uridine. This editing restores ...